IL-17i Ixekizumab (IXE) continuation superior to withdrawal in preventing relapse in PsA ● Withdrawal resulted in relapse at median 22 wk ● Continuation vs withdrawal 38% vs 85% relapse ● 96% regained control after reinstating IXE Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/TgIRe14Vud